NAD+ IV Therapy: The Route With the Least Evidence

NAD+ is sold three ways — an intravenous drip, a subcutaneous injection, and oral precursor capsules — at wildly different prices, and the pricing runs in almost exactly the opposite direction to the evidence.

The oral precursors have randomized controlled trials, systematic reviews and meta-analyses. The intravenous route, which costs the most and is marketed hardest, has essentially none. That inversion is the single most useful thing to know before booking a drip.

This is not an argument that IV NAD+ does nothing. It is an argument that the most expensive option is the one nobody has studied, which is an unusual thing to discover about a treatment and worth knowing before paying for it.

What NAD+ Is, and What It Is Not

First, a category correction that matters for a peptide site: NAD+ is not a peptide. It is a coenzyme — nicotinamide adenine dinucleotide — involved in cellular energy metabolism and a long list of enzymatic reactions. It appears on peptide menus because it is injected and sold to the same customers, not because it belongs to the same chemical class.

Its levels decline with age, and that observation is the seed of the entire market: if NAD+ falls as we age, restoring it might restore something. That is a reasonable hypothesis. It is also the same reasoning that underpins the growth-hormone anti-aging industry, which we take apart in peptides for anti-aging — a correlation with age is a hypothesis generator, not a result.

Where the Human Evidence Actually Is

The oral precursor route — nicotinamide riboside and nicotinamide mononucleotide — is where researchers have done the work, and it is instructive precisely because the results are not flattering.

Nicotinamide riboside did not alter mitochondrial respiration, content or morphology in skeletal muscle in obese, insulin-resistant men¹. That is a direct test of the mechanism the whole category is sold on, with a null result. A separate randomized trial in healthy obese humans found changes in body composition and skeletal-muscle acetylcarnitine without the energy outcome the marketing implies².

Nicotinamide mononucleotide has accumulated enough randomized trials to support systematic review — there is a systematic review and meta-analysis of safety and metabolism-related outcomes of oral NMN supplementation in adults³, and a separate meta-analysis of randomized trials on blood pressure⁴. There is also randomized work on anti-inflammatory effects in human skeletal muscle after blood-flow-restriction exercise⁵.

Whatever those studies conclude on their individual endpoints, the structural point stands: this is what an evidence base looks like. Multiple randomized trials, pooled, on defined outcomes, in humans.

Now search for the equivalent on intravenous NAD+ and it is not there. There is old parenteral NADH work in Parkinson's disease⁶ — a different molecule, a different route, a different population, three decades ago — and very little else resembling the trial program the oral route has produced.

The Bioavailability Argument, Fairly Stated

The clinic's answer to this is that IV bypasses digestion and delivers NAD+ directly, so it must work better than an oral precursor that has to be absorbed and converted.

The argument is not stupid, and it is worth engaging rather than dismissing. Intravenous delivery genuinely bypasses first-pass metabolism. Nobody disputes that an infusion puts more of the molecule in the bloodstream than a capsule does.

But two things are being conflated. Getting a molecule into the blood is not the same as getting it into cells where it is used, and NAD+ is a large, charged molecule that does not simply diffuse across cell membranes — which is precisely why the oral products supply precursors the body converts, rather than NAD+ itself. And more importantly, "better bioavailability" is a claim about a blood level, while the thing being sold is a claim about energy, focus, recovery and aging. A higher blood level is a surrogate endpoint. The whole lesson of the NAD+ literature so far is that raising the molecule and changing what happens to a person are different achievements — which is exactly what the nicotinamide riboside muscle study found¹.

So the honest position: the IV route probably does put more NAD+ in your blood. Nobody has shown that this produces an outcome, and the oral route's trials are the reason to be cautious rather than confident about assuming it would.

The Infusion Experience Is Not Nothing

Worth naming, because it affects how the evidence gets read.

NAD+ infusions are typically slow — often hours — and commonly produce sensations during administration: flushing, chest tightness, nausea, an urge to have the drip slowed down. Clinics describe this as normal and slow the rate.

That matters for a specific reason. A long, expensive, physically eventful procedure in a clinical setting is close to the maximum-strength version of a placebo context. Feeling different afterwards is exactly what you would expect from an intervention with that shape regardless of what is in the bag, which is why uncontrolled reports from IV clinics carry very little information. We make the same point about a field mature enough to measure its own placebo responses in peptides for anxiety.

The Age-Decline Argument, Examined

The reasoning underneath the whole market deserves a direct look, because it is the same reasoning that built the anti-aging hormone industry and it has a known failure mode.

The argument: NAD+ levels decline with age, aging involves reduced cellular energy metabolism, therefore restoring NAD+ should restore something.

Each step is individually plausible and the conclusion still does not follow. A molecule declining with age can be a consequence of aging rather than a cause of it, and topping it up in that case changes a number without changing anything else. Distinguishing the two requires an intervention study measuring an outcome — which is exactly the study design the oral literature has run and the IV route has not.

It is worth noticing that this is structurally identical to the growth-hormone story: a hormone declines with age, a study showed body-composition changes when it was restored, an industry followed, and the pooled evidence that eventually arrived found the changes were largely fluid with no functional benefit. We tell that story in full in peptides for anti-aging. The NAD+ market is running the same play, one decade behind, and the oral trials are the first returns coming in.

Injection, Drip, or Capsule

The three routes, compared honestly on what is known:

Oral precursors have the trials, the meta-analyses, the lowest cost and the lowest risk. They also have the least impressive results, which is not a coincidence — being studied is how a treatment ends up with unimpressive results attached to it.

Subcutaneous injection sits in between, and is what most telehealth desks sell. We cover it in NAD+ injections: the evidence.

Intravenous infusion costs the most, takes the longest, has the strongest experiential component, and has the least published human evidence of the three.

The compound sold as the oral shortcut to raising NAD+ is a different molecule again — see does 5-amino-1MQ boost NAD? and 5-amino-1MQ: the evidence. The broader energy claim across all of these is in peptides for energy.

What It Costs

IV clinic pricing is largely local and quoted per session, which puts it outside what we can verify at scale. The injectable route we do track, and the pricing there shows the usual patterns.

Live Vital repriced NAD+ in August 2026 to a straight $149/month on a three-month $447 protocol — up 80% from the earlier "$83/mo", which had been a ten-week $249 total divided by three. RxPepsDirect sells NAD+ at $100 per 1,000 mg vial and never states how long a vial lasts, with a $39 visit fee and $15 shipping on every order. ElitePhysiqMD prices NAD+ at $267.30 a month on a page advertising the category "from $161/mo".

Two are clearer: System Labs names its pharmacy with a street address and states the milligrams — 1,000 mg a month — though its $89 first-month rate has a successor that appears only as a struck-through number, and LaSara publishes a one-time price, a subscription price and a per-day cost for its NAD+ vial.

Board: best NAD+ injection providers, with figures in the price transparency index and everything on the rankings index.

Bottom Line

The evidence and the price run in opposite directions across the three NAD+ routes, and that is the finding.

Oral precursors carry the human trial program: nicotinamide riboside failed a direct test of the mitochondrial mechanism in skeletal muscle¹ and produced body-composition changes without the energy outcome in another randomized trial²; nicotinamide mononucleotide has accumulated enough randomized trials for systematic reviews and meta-analyses on safety, metabolic outcomes and blood pressure³⁴⁵. That is a real evidence base, and the results are mostly modest.

Intravenous NAD+ — the most expensive route, the one with the longest chair time and the strongest experiential component — has essentially no comparable literature. The nearest thing is decades-old parenteral NADH work in a different population⁶.

The bioavailability argument for IV is reasonable as far as it goes, and it goes as far as a blood level. Everything past that — energy, focus, recovery, aging — is the part nobody has tested by that route.

If you want to try NAD+, the honest ordering is to start with the cheapest route that has actually been studied, and treat the drip as the premium version of an unproven thing rather than the proven version of a premium one.